Sermorelin

Sermorelin is the synthetic 29-residue amide corresponding to the N-terminal portion of human growth-hormone-releasing hormone (GHRH), historically termed GHRH(1-29) or GRF(1-29). Early characterization established that this truncated fragment retains the intrinsic activity of the longer 40- and 44-residue forms, defining it as the minimal active sequence. The molecule carries a C-terminal amide and a single oxidation-sensitive methionine. Solution NMR work (Theriault et al., 1988) examined the secondary structure of GRF(1-29) and described substantial alpha-helical character in a membrane-mimetic solvent system, providing an early structural model for how the peptide is organized. For molecular identity, the research literature anchors the free-peptide form to a defined formula and mass; salt forms (e.g. the acetate) are catalogued separately and are distinguished by their own registry identifiers.

The molecule's target, the GHRH receptor (GHRHR), is a class B1 GPCR structurally related to the secretin and VIP receptors and expressed predominantly on pituitary somatotrophs. The receptor was cloned and characterized from pituitary tissue (Mayo, 1992; with parallel work by the Thorner group), establishing a recombinant system in which GHRH bound the receptor and stimulated cAMP production. Genetic studies of the 'little' mouse (Godfrey et al., 1993) mapped a receptor mutation to the extracellular domain, linking GHRHR function to somatotroph biology. Mechanistic models describe agonist engagement coupling to Gs, raising cAMP, activating PKA, and phosphorylating CREB, which together with the Pit-1 transcription factor is associated with growth-hormone gene transcription. A two-domain ('two-step') binding model is used to describe how the peptide contacts both the receptor's extracellular domain and its transmembrane core.

Structural work (Zhou et al., 2020) reported a cryo-EM structure of the GHRH-GHRHR-Gs complex, resolving how the alpha-helical peptide contacts the receptor extracellular loops, the extracellular domain, and the transmembrane helices, and mapping reported loss-of-function receptor variants onto the structure. This structure is commonly cited as a reference framework for interpreting GHRH-receptor pharmacology and for situating fragment analogs such as sermorelin within the broader GHRH structure-activity literature.

GHRH(1-29) has been used as a research tool for probing pituitary function. A review by Prakash and Goa (1999) surveyed its use in pituitary provocative-testing research, where it is examined for its relative specificity as a pituitary-level probe. In aging-related somatotropic-axis research, several studies examined GHRH(1-29) and close analogs - Corpas et al. (1992) and Vittone et al. (1997) studied GHRH(1-29), and Khorram et al. (1997) examined a stabilized [Nle27]GHRH(1-29) analog. A pediatric growth-physiology study (Thorner et al., 1996) examined GHRH(1-29) in a growth-research context. A registered study (ClinicalTrials.gov NCT03018886) examined a GHRH analog combined with arginine within an adult pituitary-function diagnostic research paradigm, assessing serum growth-hormone response as its measured endpoint.

As a small unmodified peptide, sermorelin is characterized in the literature by rapid clearance from the circulation and a short circulating half-life on the order of minutes. This short residence time is consistent with its experimental use to evoke a single physiological growth-hormone pulse rather than continuous receptor occupancy, and it distinguishes the unmodified fragment from longer-acting, chemically stabilized GHRH analogs that carry acyl or amino-acid-substitution modifications to resist proteolysis.

Some literature frequently grouped with sermorelin actually studied distinct molecules that share the GHRHR target, and the distinction is preserved here. Cognition and sleep-architecture research in older adults (Baker et al., 2012) used a related, stabilized GHRH analog rather than sermorelin itself. Cardiovascular findings in rodent and cell models (Kanashiro-Takeuchi et al., 2010, 2012) used synthetic GHRH-receptor agonists, again not sermorelin, and examined GHRHR expression on cardiac cells. The foundational discovery of growth-hormone-releasing factor from pancreatic tumor tissue (Guillemin et al., 1982; Rivier et al., 1982) and the subsequent isolation and synthesis of the human hypothalamic peptide (Ling et al., 1984) established the parent GHRH on which the sermorelin fragment is based. Contemporary reviews (Granata et al., 2025; Montero-Hidalgo et al., 2025; Lin-Su and Wajnrajch, 2002) synthesize GHRH and GHRHR biology across these research areas.